Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS).
Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Full Title of Study: “Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2024
- Drug: ranibizumab, aflibercept, pegaptanib, verteporphin
- ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
Arms, Groups and Cohorts
- Other: Macular disease with adequate treatments
- Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
Clinical Trial Outcome Measures
- Change of best-collected visual acuity from baseline at 5 years
- Time Frame: Five years after the registration
Participating in This Clinical Trial
- Patients who visit Department of Ophthalmology, Kagawa University Hospital with macular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS.
- Patients who are agreed with the participation of this study.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Kagawa University
- Provider of Information About this Clinical Study
- Principal Investigator: Akitaka Tsujikawa, Professor and Chairman – Kagawa University
- Overall Official(s)
- Akiataka Tsujikawa, MD, Principal Investigator, Kagawa Univerisity Faculty of Medicine
- Overall Contact(s)
- Chika Akuta, +81-87-891-2211, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.